Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-25

Clinical Trial Update: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial update for SPD489 in preschool children with ADHD reports on safety, tolerability, pharmacokinetics, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPD489

Snippet

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Status: COMPLETED | Results posted: 2018-10-25